The global antibodies contract manufacturing market was valued at USD 17.79 billion in 2024 and is expected to reach USD 31.76 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.1% from 2025 to 2030. The increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics significantly drives this market growth.

 

These antibody therapies have demonstrated effectiveness in treating a range of conditions, including cancers, rheumatoid arthritis, and other chronic diseases, thereby boosting the demand for therapeutic antibody production. This rising demand is expanding the antibody contract manufacturing market as companies strive to scale production to meet the evolving needs of healthcare providers and patients.

 

Biopharmaceutical manufacturing is recognized as a leading sector with considerable growth potential. Many healthcare stakeholders believe this sector will emerge as one of the top 10 revenue generators in the coming years. Furthermore, market players are continuously advancing this sector to address the growing demand for bio-based pharmaceuticals, which is expected to lead to a surge in Contract Manufacturing Organizations (CMOs) for biopharmaceutical production. For example, in February 2024, Catalent's acquisition by Novo Holdings, along with the expansion of its European facilities, enhanced its antibody production capabilities, particularly targeting small molecules and biologics for advanced therapies. This expansion is in line with their strategy to augment therapeutic offerings, including cell and gene therapies, contributing to a robust product pipeline.

 

Key Market Trends & Insights

  • North America: The antibody contract manufacturing market in North America led the global market in 2024, holding around 34.17% share. This dominance is due to extensive biopharmaceutical manufacturing in the region and the presence of numerous CDMO/CMO facilities. Legislation regarding biological development in the region is expected to significantly influence the progress of biopharmaceutical contract manufacturing.
  • Product Segmentation: Monoclonal antibodies (mAbs) represented the largest product segment with a 76.42% share as of 2024. mAb formulations are increasingly preferred as targeted therapies for various lung conditions, including lung cancer, infections, and asthma.
  • Source Segmentation: The mammalian source segment captured the largest market share at 57.52% in 2024. In response to the growing demand for antibody contract manufacturing services, several CMOs are expanding their mammalian cell culture production capacities. The mammalian cell expression system is favored for mAb production due to its ability to process, produce, and secrete complex molecules effectively.
  • End Use Segmentation: The biopharmaceutical companies segment accounted for over 66.49% of the market share in 2024 and is projected to be the fastest-growing segment during the forecast period. These companies play a pivotal role in developing innovative treatments for patients globally.

 

Order a free sample PDF of the Antibodies Contract Manufacturing Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

  • 2024 Market Size: USD 17.79 Billion
  • 2030 Projected Market Size: USD 31.76 Billion
  • CAGR (2025-2030): 10.1%
  • North America: Largest market in 2024

 

Key Companies & Market Share Insights

International partnerships are a vital strategy among market players. For instance, U.S. CMOs are increasingly collaborating with counterparts in the Swiss pharmaceutical sector. Additionally, the major CMOs are expanding to meet market demands and maintain a competitive edge.

 

Key Players

  • Lonza
  • Samsung Biologics
  • WuXi Biologics.
  • Charles River Laboratories
  • FUJIFILM Holdings Corporation
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • AGC Biologics
  • Cytovance Biologics, Inc.
  • EMERGENT
  • Thermo Fisher Scientific
  • Labcorp Drug Development
  • Catalent, Inc.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The antibodies contract manufacturing market is poised for substantial growth, driven by the increasing demand for therapeutic antibodies and the expansion of biopharmaceutical manufacturing capabilities. As companies adapt to meet the evolving needs of healthcare providers and patients, strategic collaborations and technological advancements will play crucial roles in shaping the future landscape of this dynamic market.